<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157945">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01741493</url>
  </required_header>
  <id_info>
    <org_study_id>M13-845</org_study_id>
    <nct_id>NCT01741493</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494</brief_title>
  <official_title>A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose
      study in healthy volunteers, multiple dose study in patients with rheumatoid arthritis and
      multiple dose study in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the safety, tolerability and pharmacokinetics of ABT-494 in healthy volunteers and
      in patients with rheumatoid arthritis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
  <primary_outcome>
    <measure>Number and percentage of participants with Adverse Events</measure>
    <time_frame>From first dose up to 28 days after the last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>From first dose up to 28 days after the last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Blood pressure, pulse rate and body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Lab testing</measure>
    <time_frame>From date of first dose up to 28 days after the last dose of study drug</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Hematology, Chemistry, and Urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>Prior to first dose, during first dose interval, prior to last dose and until 24 hours post last dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ECGs done in triplicate; heart rate, PR interval, QT/QTc interval and QRS duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ABT-494</measure>
    <time_frame>Prior to first dose up to 72 hours after the last dose of ABT-494</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax, Tmax, AUC, elimination rate constant and half-life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Methotrexate</measure>
    <time_frame>Prior to first dose up to 48 hours after the last dose of methotrexate</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax, Tmax, AUC, elimination rate constant and half-life</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers (ABT-494)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dosing of ABT-494 in healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dosing of ABT-494 in patients with rheumatoid arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administration in healthy volunteers and patients with rheumatoid arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Volunteers (tofa)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Multiple dosing of tofacitinib in healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-494</intervention_name>
    <description>Oral administration of ABT-494 capsules</description>
    <arm_group_label>Healthy Volunteers (ABT-494)</arm_group_label>
    <arm_group_label>Rheumatoid Arthritis Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of placebo capsules</description>
    <arm_group_label>No treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>Healthy Volunteers (tofa)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Volunteers:

          -  Male and female subjects 18 to 55 years of age, inclusive.

          -  Subject is judged to be in good general health.

        Rheumatoid Arthritis Patients:

          -  Male and female patients 18 to 75 years of age, inclusive.

          -  Subject has a diagnosis of rheumatoid arthritis for at least six months.

          -  Subject has been on methotrexate therapy for at least three months and on a stable
             dose for at least four weeks.

        Exclusion Criteria:

          -  History or evidence of active or latent tuberculosis.

          -  History or significant allergic reaction to any drug.

          -  Use of known strong CYP3A and CYP2D6 inhibitors and CYP3A inducers within 21 days or
             within 5 half-lives of the respective medication, whichever is longer.

          -  Current or expected need for oral intake of at least 10 mg prednisone per day or
             equivalent corticosteroid therapy.

          -  History of acute inflammatory joint disease of different origin other than rheumatoid
             arthritis (rheumatoid arthritis patients).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven  Jungerwirth, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 95817</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 95816</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 95815</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 92153</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 97177</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 3, 2014</lastchanged_date>
  <firstreceived_date>December 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Tofacitinib</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
